John J. Frazer v. United States of America; John J. Frazer v. P. Mullins, et al.

CourtDistrict Court, E.D. Kentucky
DecidedJanuary 26, 2026
Docket5:23-cv-00193
StatusUnknown

This text of John J. Frazer v. United States of America; John J. Frazer v. P. Mullins, et al. (John J. Frazer v. United States of America; John J. Frazer v. P. Mullins, et al.) is published on Counsel Stack Legal Research, covering District Court, E.D. Kentucky primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
John J. Frazer v. United States of America; John J. Frazer v. P. Mullins, et al., (E.D. Ky. 2026).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF KENTUCKY CENTRAL DIVISION LEXINGTON

JOHN J. FRAZER, ) ) Plaintiff, ) No. 5:24-CV-177-REW-CJS ) V. ) ) UNITED STATES OF AMERICA, ) OPINION & ORDER ) Defendant. )

and

JOHN J. FRAZER, ) ) Plaintiff, ) No. 5:23-CV-193-REW-CJS ) V. ) ) P. MULLINS, et al., ) OPINION & ORDER ) Defendants. )

*** *** *** *** This is a consolidated case. Plaintiff John Frazer filed two motions seeking judgment in his favor. In the first, he seeks summary judgment against eleven defendants on his claims asserted pursuant to Bivens v. Six Unknown Named Agents of Fed. Bureau of Narcotics, 91 S. Ct. 1999 (1971). See DE 26 (Motion for Summary Judgment). In the second, Frazer seeks summary judgment against the United States on his claim asserted pursuant to the Federal Tort Claims Act (“FTCA”), 28 U.S.C. §§ 1346(b), 2671 et seq. See DE 32 (Motion for Summary Judgment). Defendants responded to each motion. See DE 34 (Response to Motion for Summary Judgment on FTCA Claims); DE 36 (Response to Motion for Summary Judgment on Bivens Claims). There was no reply. The defense also filed a cross-motion seeking summary judgment on both of Frazer’s claims. See DE 33 (Defendants’ Motion for Summary Judgment). Frazer responded, see DE 40 (Plaintiff’s Response to Defendants’ Motion for Summary Judgment), to which Defendants have replied, see DE 41 (Defendants’ Reply). All of the motions are fully briefed and ripe for review.1

I. Factual Background Frazer is currently confined at the Federal Medical Center in Lexington, Kentucky. See DE 33 at 2. Frazer has an extensive medical history dating back to his childhood, which includes “hypertension, anemia, renal osteodystrophy, heart failure with preserved ejection fraction, coronary artery disease with a history of percutaneous stent placements in the past[,] type 2 diabetes mellitus[,] chronic pancreatitis, SVC obstruction hyperlipidemia, depression and anxiety.” See DE 33-1 at 2 (Progress Notes); see also DE 33-52 (March 17, 2025, Expert Report of Dr. Paul Fitzgerald) at 3-4. Medical records from 2024 list nearly two dozen medications Frazer takes at varying intervals.3 See DE 33-1 at 4-6 (Current Outpatient Medications). From 2014 until 2022, Frazer was incarcerated at the Federal Medical Center in Rochester,

Minnesota. See DE 33-2 (Frazer Deposition) at 8. Because of his chronic pancreatitis, Frazer’s

1 Frazer filed his separate Bivens complaint in June 2023. See Frazer v. Mullins et al., No. 5:23-CV-193- REW-CJS (E.D. Ky. 2023), DE 1 (Complaint). He filed his FTCA complaint in this action in July 2024. See Frazer v. United States, No. 5:24-CV-177-REW-CJS (E.D. Ky. 2024), DE 1 (Complaint). The two cases were administratively consolidated in April 2025, with this case designated as the lead action. See DE 25 (Order). Unless otherwise indicated, all references to docket entries shall be to those found in the lead action. 2 The Court denied Frazer’s motion to exclude any expert testimony by Dr. Fitzgerald. See DE 44 (Order); DE 27 (Motion to Exclude). Frazer did not renew this objection in his summary judgment briefings. Regardless, as evident in the analysis below, the Court’s references to Dr. Fitzgerald’s report would not be subject to exclusion and was not, itself, dispositive. 3 The Bureau of Prisons (“BOP”) maintains medical records in an electronic database, the Bureau Electronic Medical Record (“BEMR”). See DE 33-3 (Hobbs Decl.) at 3 ¶ 4. Within the BEMR, healthcare providers input information into the Medication Administration Record (“MAR”) detailing what medications are administered, by whom, and at what time and dose. See id. at 3 ¶ 5. pancreas “still produces insulin, but it’s sporadic. It’s, it can kind of shoot-out insulin whenever it decides it wants to, it seems like, which is why I’m kind of sensitive to insulin.” See id. at 18-19. It was not until 2016 or 2017 that Frazer was first diagnosed with diabetes, and he was prescribed insulin shortly thereafter. See id. at 20-21. After some trial and error, physicians working on

behalf of the BOP placed Frazer on a “sliding scale” insulin dosage based upon his blood glucose readings for a given point in the day.4 See DE 33-2 at 23. Under the sliding scale approach, Frazer receives between one and five units of insulin depending upon his most recent blood glucose reading, with higher doses administered as his blood glucose readings elevate. See id. at 23, 32. Specifically, Frazer’s sliding scale prescription for insulin directed healthcare staff to “[i]nject subcutaneously twice daily per sliding scale: BG [blood glucose, presumably] 150-199 = 1 unit; 200-249 = 2 units, 250-299 = 3 units, 300-349 = 4 units, 350-399 = 5 units, 400 or higher = 5 units & contact provider.” See DE 33-4 at 11 (cleaned up). Nonetheless, while at FMC-Rochester, Frazer felt that his diabetes was not well controlled because his daily blood glucose levels fluctuated widely. See DE 33-2 at 24.

When Frazer transferred to FMC-Lexington in 2022, his diabetes prescription remained unchanged and used the same sliding scale. See DE 33-2 at 24, 32-34. Although Frazer’s prescription directs that he receive insulin in the morning, he testified that he chooses not to take that dose because he does not eat breakfast. See id. at 27. Instead, Frazer first uses his glucometer to take a reading of his blood sugar shortly before he has lunch. See id. at 27-28. Just after lunch,

4 See also DE 33-3 (Declaration of Jacquelyn Hobbs) at 2 ¶ 2 (“Insulin glargine is a long-acting insulin injected once daily and provides a basal insulin level throughout the day. Sliding scale insulin involves the administration of an increasing dose of insulin based on the inmates [sic] self-reported blood sugar levels and is administered three times daily. Inmates are responsible for checking their blood sugar level just prior to insulin line and reporting the blood sugar level to the member of the nursing staff who is administering the insulin.”). Frazer proceeds to the insulin line at the health department and reports his blood sugar level to a nurse.5 Depending on what he ate for lunch, Frazer then decides whether or not he wants to receive an insulin injection from the nurse for the afternoon.6 See id. at 28-31. Frazer tests his blood sugar again at around 4 p.m. and reports it to the nurse, who

administers insulin according to the sliding scale. See id. at 31-34. Independent of the sliding scale insulin, the nurse would also inject the slow-acting glargine insulin. See id. at 34; see, e.g., DE 33-4 at 12, 14, 17. If Frazer started experiencing low blood sugar in the evening, he would swallow a glucose tablet or eat a snack with high carbohydrates. See DE 33-2 at 39, 42. Frazer kept a substantial stockpile of snacks that he had purchased from the commissary for this purpose. See id. at 49-50. In March 2023, Frazer obtained a copy of his MAR. Frazer testified that those records showed that nurses had frequently administered the highest dose - five units of insulin - without regard to the blood glucose number that he reported to them.7 See DE 33-2 at 34, 36. Indeed, on the days where Frazer showed up at the evening pill line and requested insulin, most of the MAR

entries show five units were administered. See generally DE 1-2. On days indicating the

5 See DE 33-3 at 2 ¶ 2 (“During insulin line, which is conducted three times daily, inmates report to the institution’s central clinic where insulin is administered through subcutaneous injection.”). Frazer’s self- reported blood glucose numbers are recorded in the “Comments” section of the MAR. See, e.g., DE 1-2 at 3, 6; DE 26 at 7. 6 Consistent with his deposition testimony, the MAR shows that Frazer was a consistent “No Show” for the morning insulin line.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Brian Viergutz v. Lucent Technologies, Inc.
375 F. App'x 482 (Sixth Circuit, 2010)
United States v. Gilman
347 U.S. 507 (Supreme Court, 1954)
Rayonier Inc. v. United States
352 U.S. 315 (Supreme Court, 1957)
United States v. Orleans
425 U.S. 807 (Supreme Court, 1976)
Estelle v. Gamble
429 U.S. 97 (Supreme Court, 1976)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Wilson v. Seiter
501 U.S. 294 (Supreme Court, 1991)
Federal Deposit Insurance v. Meyer
510 U.S. 471 (Supreme Court, 1994)
Scott v. Harris
550 U.S. 372 (Supreme Court, 2007)
Jones v. Muskegon County
625 F.3d 935 (Sixth Circuit, 2010)
Alspaugh v. McConnell
643 F.3d 162 (Sixth Circuit, 2011)
James Lyons v. RN/HSA Suzanne Brandly
430 F. App'x 377 (Sixth Circuit, 2011)
Allen Friedman v. United States
927 F.2d 259 (Sixth Circuit, 1991)
Lomando v. United States
667 F.3d 363 (Third Circuit, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
John J. Frazer v. United States of America; John J. Frazer v. P. Mullins, et al., Counsel Stack Legal Research, https://law.counselstack.com/opinion/john-j-frazer-v-united-states-of-america-john-j-frazer-v-p-mullins-kyed-2026.